HMG CoA reductase inhibition modulates VEGF-induced endothelial cell hyperpermeability by preventing RhoA activation and myosin regulatory light chain phosphorylation
about
Narrative review: the systemic capillary leak syndromeRho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunitiesFunctions of nonmuscle myosin II in assembly of the cellular contractile systemRk1, a ginsenoside, is a new blocker of vascular leakage acting through actin structure remodelingIdentification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions.Dynamic regulation of vascular myosin light chain (MYL9) with injury and aging.RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis.Simvastatin attenuates ventilator-induced lung injury in mice.Simvastatin reduces endotoxin-induced acute lung injury by decreasing neutrophil recruitment and radical formation.MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy.Peptide nanofibers preconditioned with stem cell secretome are renoprotective.The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPasesSimvastatin reverses podocyte injury but not mesangial expansion in early stage type 2 diabetes mellitusSparse feature selection methods identify unexpected global cellular response to strontium-containing materials.Inhibition of CXCL16 attenuates inflammatory and progressive phases of anti-glomerular basement membrane antibody-associated glomerulonephritis.Combined treatment of Aβ immunization with statin in a mouse model of Alzheimer's disease.Statins and the vascular endothelial inflammatory responseEndothelial cell barrier protection by simvastatin: GTPase regulation and NADPH oxidase inhibitionDynamics of neutrophil extravasation and vascular permeability are uncoupled during aseptic cutaneous wounding.Simvastatin alleviates hyperpermeability of glomerular endothelial cells in early-stage diabetic nephropathy by inhibition of RhoA/ROCK1.Molecular mechanisms of endothelial hyperpermeability: implications in inflammation.New insights into molecular mechanisms of diabetic kidney disease.Rho kinase inhibition in diabetic kidney disease.Integrin alphavbeta5 regulates lung vascular permeability and pulmonary endothelial barrier function.ROCK as a Therapeutic Target of Diabetic RetinopathyLovastatin inhibits the thrombin-induced loss of barrier integrity in bovine corneal endothelium.Protein kinase Calpha-RhoA cross-talk in CCL2-induced alterations in brain endothelial permeability.
P2860
Q24603534-74F5E9B3-8321-49A4-B9F6-00F206CDCA2BQ26778344-944D7AEC-8A2F-4593-9B81-76FF8628E665Q27333965-3F017835-A707-4625-B79D-194CDD074DBAQ28534764-D0F8A5E6-5600-4787-8682-ACEFFD5D46F2Q34004047-4BCBEBB1-2E1F-4EB8-8BF2-4931A6EF2100Q34049347-6CDEBC02-D1DE-4710-BB5F-1349C4B2BC43Q34072195-17FCDF80-910A-4A4D-8ACD-18298C19AEB0Q34153309-B6D52B01-8690-4ED9-804B-A74A71E83213Q34305806-B1B70D4C-43EB-486A-ABB1-7F6F3002274BQ34719895-E54B58D4-C1E8-4B25-AD22-BD1E6AC4953DQ34726874-B7E54899-694E-4938-98C0-7D788A4F8976Q34924413-2F9F5AB1-50D6-4E5C-9BB5-47D48AE13915Q35098290-10541ACD-9FCE-4E37-95E1-8DE5A8986C29Q35378307-FDF106C6-5BBA-4DC4-973D-0EF6CCBB2441Q35757157-B9A38495-7908-4494-87CC-4901AB262DF1Q35818921-945D96FA-C809-45B6-A0F9-2D3911EA56C4Q36695979-1DEE9DC7-AEF3-4EAF-9F4D-F797D412B558Q36956158-ECD93FE0-0CDB-48C6-8E63-E186D4B801F5Q37162381-ECC237BE-EEC4-4FFB-9B74-ADFC3173B349Q37308921-BD031AB4-E6A4-46F8-A20C-34EE4579319BQ37535022-4B774F24-3628-45C4-8EA3-2F9C74BB73B0Q37598306-CA4D03E2-F389-4581-B335-3D893F149AB6Q38117171-771C343B-2051-4751-8165-10CF87750860Q41811902-5A675A77-0158-49C3-92E6-8F76E663D165Q41873958-6E430158-F2EC-4A75-92EC-2A214FFA70E3Q42068602-B813BE30-67EE-4547-B784-5C53E8121406Q46913501-494BEB8E-7F13-4F66-BB24-C34921BC86FC
P2860
HMG CoA reductase inhibition modulates VEGF-induced endothelial cell hyperpermeability by preventing RhoA activation and myosin regulatory light chain phosphorylation
description
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2005
@ast
im November 2005 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2005/11/01)
@sk
vědecký článek publikovaný v roce 2005
@cs
wetenschappelijk artikel (gepubliceerd op 2005/11/01)
@nl
наукова стаття, опублікована в листопаді 2005
@uk
مقالة علمية (نشرت في نوفمبر 2005)
@ar
name
HMG CoA reductase inhibition m ...... ry light chain phosphorylation
@ast
HMG CoA reductase inhibition m ...... ry light chain phosphorylation
@en
HMG CoA reductase inhibition m ...... ry light chain phosphorylation
@nl
type
label
HMG CoA reductase inhibition m ...... ry light chain phosphorylation
@ast
HMG CoA reductase inhibition m ...... ry light chain phosphorylation
@en
HMG CoA reductase inhibition m ...... ry light chain phosphorylation
@nl
prefLabel
HMG CoA reductase inhibition m ...... ry light chain phosphorylation
@ast
HMG CoA reductase inhibition m ...... ry light chain phosphorylation
@en
HMG CoA reductase inhibition m ...... ry light chain phosphorylation
@nl
P2093
P356
P1433
P1476
HMG CoA reductase inhibition m ...... ry light chain phosphorylation
@en
P2093
Eudora Eng
Farhad R. Danesh
Lixia Zeng
Mehran M. Sadeghi
Stephen Adler
Teng-Leong Chew
Yashpal S. Kanwar
P304
P356
10.1096/FJ.05-4240FJE
P407
P577
2005-11-01T00:00:00Z